|Bid||12.660 x 0|
|Ask||12.680 x 0|
|Day's Range||12.560 - 12.960|
|52 Week Range||10.020 - 18.180|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||14.35|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||0.56 (4.46%)|
|Ex-Dividend Date||Apr 26, 2022|
|1y Target Est||17.61|
Recently, China Medical System ("CMS", 0867.HK) announced its annual results. After recording continuous performance growth in the difficult time of the pandemic in 2020, it once again achieved a new record high, with revenue of RMB 8,337 million, up 20.0% year-on-year, and net profit of RMB 3,025 million, up 18.4% year-on-year.
Recently, Morgan Stanley Capital International (MSCI), the world's largest index provider, has updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited ("CMS" or the "Company"). CMS's latest rating remains unchanged at "AA", surpassing 83% of the companies in the pharmaceutical industry, which indicates the Company has maintained leading position in ESG management among its global peers.
China Medical System Holdings Limited ("CMS", or the "Company", SEHK: 867), together with its subsidiaries (the "Group"), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, announced its unaudited results for the 6 months ended 30 June 2021 (the "Reporting Period").